BioWorld

Sep. 18, 2002

View Archived Issues

Genentech, XOMA Come Through With Strong Phase III Raptiva Data

When trying to get a drug approved, biotechnology companies must provide the FDA with data - data showing that a drug is efficacious, that it works in the appropriate patient and that it is safe, among other things. (BioWorld Today) Read More

Trimeris, Roche Submit NDA Seeking Approval Of Fuzeon

Read More

Little-Known MSR1 Gene Links Prostate Cancer, Heart Disease, Macrophages, Atherosclerosis

Read More

IDEC Collaborates With Caprion On Proteomics-Based Discovery

Read More

Other News To Note

Read More

Onyx Regains Remainder Of Rights To ONYX-015 Program

Read More